Boiron SA (BOI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Boiron SA (Boiron) is a pharmaceutical company. It develops, manufactures and commercializes homeopathic medicines. The company operates through two reportable business segments, namely, Non-proprietary homeopathic medicines, associated with precise therapeutic indications and dosage; and OTC specialties, no specific therapeutic indication or dosage. Its product portfolio comprises Camilia, Euphralia, Arnigel, Oscillococcinum, Sedatif PC, Homeoptic and Stodal. The company has operations in various countries across the world including France, Italy, Spain, Belgium, Switzerland, Germany, the Netherlands, Portugal, Czech Republic, Slovakia, Romania, Hungaria, Poland, Bulgaria, the US, Canada, Tunisia, Morocco, Russia and Brazil. It also manages five production facilities in France and Belgium. Boiron is headquartered in Sainte-Foy-les-Lyon, France.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table Of Contents
Boiron SA (BOI) - Financial and Strategic SWOT Analysis Review Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Section 1 - About the Company 6 Boiron SA - Key Facts 6 Boiron SA - Key Employees 7 Boiron SA - Key Employee Biographies 8 Boiron SA - Major Products and Services 9 Boiron SA - History 10 Boiron SA - Company Statement 12 Boiron SA - Locations And Subsidiaries 13 Head Office 13 Other Locations and Subsidiaries 13 Section 2 - Company Analysis 16 Boiron SA - Business Description 16 Boiron SA - Corporate Strategy 17 Boiron SA - SWOT Analysis 18 SWOT Analysis - Overview 18 Boiron SA - Strengths 18 Strength - Advanced RandD Activities 18 Strength - Operational Network 18 Boiron SA - Weaknesses 19 Weakness - Legal Proceedings 19 Weakness - Decline in Product Sales Affects Revenue 19 Boiron SA - Opportunities 20 Opportunity - Strategic Initiatives 20 Opportunity - Market Potential: Homeopathy 20 Opportunity - Products in Pipeline 20 Boiron SA - Threats 21 Threat - Prejudice Against Homeopathy 21 Threat - Uncertain RandD Outcomes 21 Threat - Growing Parallel Trade 21 Boiron SA - Key Competitors 22 Section 3 - Company Financial Ratios 23 Financial Ratios - Capital Market Ratios 23 Financial Ratios - Annual Ratios 24 Performance Chart 26 Financial Performance 26 Financial Ratios - Interim Ratios 27 Financial Ratios - Ratio Charts 28 Section 4 - Company's Lifesciences Financial Deals and Alliances 29 Boiron SA, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 29 Boiron SA, Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 30 Boiron SA, Recent Deals Summary 31 Section 5 - Company's Recent Developments 32 Aug 29, 2014: Boiron Reports Revenue Of â¬261.6m In H1 2014 32 Apr 08, 2014: Boiron Reports Revenue Of â¬617.7m In 2013 33 Section 6 - Appendix 34 Methodology 34 Ratio Definitions 34 About GlobalData 38 Contact Us 38 Disclaimer 38
List of Tables Boiron SA, Key Facts 6 Boiron SA, Key Employees 7 Boiron SA, Key Employee Biographies 8 Boiron SA, Major Products and Services 9 Boiron SA, History 10 Boiron SA, Subsidiaries 13 Boiron SA, Key Competitors 22 Boiron SA, Ratios based on current share price 23 Boiron SA, Annual Ratios 24 Boiron SA, Interim Ratios 27 Boiron SA, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 29 Boiron SA, Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 30 Boiron SA, Recent Deals Summary 31 Currency Codes 34 Capital Market Ratios 34 Equity Ratios 35 Profitability Ratios 35 Cost Ratios 36 Liquidity Ratios 36 Leverage Ratios 37 Efficiency Ratios 37
List of Figures Boiron SA, Performance Chart (2010 - 2014) 26 Boiron SA, Ratio Charts 28 Boiron SA, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 29 Boiron SA, Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 30